Blood–brain barrier models : in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics

From National Research Council Canada

DOIResolve DOI: https://doi.org/10.1517/17460441.2015.974545
AuthorSearch for: 1 ; Search for: 2 ; Search for: 2 ; Search for: 1 
Name affiliation
  1. National Research Council Canada. Human Health Therapeutics
  2. National Research Council Canada
FormatText
TypeArticle
Journal titleExpert Opinion on Drug Discovery
ISSN1746-0441
Volume10
Issue2
Pages141–155; # of pages: 15
Subjectbiomarkers; blood–brain barrier; in vitro blood–brain barrier models; stem cells
Abstract
The majority of therapeutics, small molecule or biologics, developed for the CNS do not penetrate the blood–brain barrier (BBB) sufficiently to induce pharmacologically meaningful effects on CNS targets. To improve the efficiency of CNS drug discovery, several in vitro models of the BBB have been used to aid early selection of molecules with CNS exposure potential. However, correlative studies suggest relatively poor predictability of in vitro BBB models underscoring the need to combine in vitro and in vivo BBB penetration assessment into an integrated preclinical workflow.
Publication date
PublisherTaylor & Francis Group
LanguageEnglish
Peer reviewedYes
NRC numberNRC-HHT-53275
NPARC number21275154
Export citationExport as RIS
Report a correctionReport a correction
Record identifierba8b53a4-5b2c-4342-bb48-92ee7f85c7c1
Record created2015-05-21
Record modified2016-05-09
Date modified:
Report a problem on this page